ethyl 2-(azepan-1-yl)acetate | 99176-11-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-(azepan-1-yl)acetate
• 英文别名: hexahydroazepin-1-yl-acetic acid ethyl ester；Hexahydroazepin-1-yl-essigsaeure-aethylester；Ethyl azepan-1-ylacetate
• CAS: 99176-11-1
• 化学式: C₁₀H₁₉NO₂
• mdl: MFCD06080426
• 分子量: 185.266
• InChiKey: ROESXCPJJVXAQV-UHFFFAOYSA-N

物化性质

• 沸点：
  96-97 °C(Press: 6 Torr)
• 密度：
  0.9852 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  ethyl 2-(azepan-1-yl)acetate 在 盐酸 、 三乙胺 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 21.17h， 生成 4-nitrophenyl 2-(azepan-1-yl)acetate hydrochloride
  参考文献：
  名称：

  串联钯和异硫脲中继催化：通过烯丙基胺化和[2,3]-正向重排对映选择性合成α-氨基酸衍生物

  摘要：

  已经开发了使用Pd和异硫脲催化的串联中继催化方案，用于从容易获得的N，N-二取代的甘氨酸芳基酯和烯丙基磷酸酯对映体选择性地合成包含两个立构中心的α-氨基酸衍生物。优化的过程使用了稳定的基于琥珀酰亚胺的Pd预催化剂（FurCat）来促进Pd催化的烯丙基磷酸酯和甘氨酸芳基酯生成的烯丙基铵盐。异硫脲苯并四咪唑催化的随后原位对映选择性[2,3]-σ重排形成syn具有高非对映选择性和对映选择性的-α-氨基酸衍生物。使用4-硝基苯基甘氨酸酯时，该方法最有效，并且可以耐受各种取代的肉桂酸和苯乙烯基烯丙基烯丙基乙基磷酸酯。在不影响立体选择性的情况下，在催化中继条件下也可以耐受使用具有挑战性的不对称N-烯丙基-N-甲基甘氨酸酯。

  DOI：

  10.1021/jacs.7b05619
• 作为产物：
  描述：

  环己亚胺 、 溴乙酸乙酯 以 四氢呋喃 为溶剂， 反应 0.5h， 以94%的产率得到ethyl 2-(azepan-1-yl)acetate
  参考文献：
  名称：

  串联钯和异硫脲中继催化：通过烯丙基胺化和[2,3]-正向重排对映选择性合成α-氨基酸衍生物

  摘要：

  已经开发了使用Pd和异硫脲催化的串联中继催化方案，用于从容易获得的N，N-二取代的甘氨酸芳基酯和烯丙基磷酸酯对映体选择性地合成包含两个立构中心的α-氨基酸衍生物。优化的过程使用了稳定的基于琥珀酰亚胺的Pd预催化剂（FurCat）来促进Pd催化的烯丙基磷酸酯和甘氨酸芳基酯生成的烯丙基铵盐。异硫脲苯并四咪唑催化的随后原位对映选择性[2,3]-σ重排形成syn具有高非对映选择性和对映选择性的-α-氨基酸衍生物。使用4-硝基苯基甘氨酸酯时，该方法最有效，并且可以耐受各种取代的肉桂酸和苯乙烯基烯丙基烯丙基乙基磷酸酯。在不影响立体选择性的情况下，在催化中继条件下也可以耐受使用具有挑战性的不对称N-烯丙基-N-甲基甘氨酸酯。

  DOI：

  10.1021/jacs.7b05619

文献信息

• Indazole compounds and methods of use thereof
  申请人：Bhagwat S. Shripad

  公开号：US20060004043A1

  公开（公告）日：2006-01-05

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防广泛的疾病和紊乱方面具有实用性，这些疾病和紊乱对激酶的抑制、调节或调控具有反应性，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病有关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛和其他疾病。因此，本发明还揭示了治疗或预防此类疾病和紊乱的方法，以及包含一种或多种吲唑化合物的药物组成物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，它们在蛋白激酶调节方面具有强效活性。因此，本发明包括口服活性分子以及可用于治疗与蛋白激酶信号转导相关的疾病或紊乱的肠外活性分子，其剂量或血清浓度较低。
• INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Bhagwat Shripad S.

  公开号：US20090099178A1

  公开（公告）日：2009-04-16

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseases or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防许多对激酶的抑制、调节或调控具有反应性的疾病和障碍方面具有用途，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉粥样硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病相关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛等。因此，本发明还揭示了治疗或预防这些疾病和障碍的方法，以及包含一种或多种吲唑化合物的制药组合物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，这些分子在调节蛋白激酶方面具有强效活性。因此，本发明包括口服活性分子和经肠道给药的活性分子，可用于治疗与蛋白激酶信号转导相关的疾病或障碍，且可用较低剂量或血清浓度。
• Indazole compounds and methods of use thereof as protein kinase inhibitors
  申请人：SIGNAL PHARMACEUTICALS, INC.

  公开号：EP2065383A1

  公开（公告）日：2009-06-03

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶液剂和水合物。吲唑化合物可用于治疗或预防对激酶的抑制、调节或调控有反应的多种疾病和失调，如炎症性疾病、异常血管生成及其相关疾病、癌症、动脉粥样硬化、心血管疾病、肾脏疾病、自身免疫性疾病、黄斑变性、与疾病相关的消瘦、与石棉相关的疾病、肺动脉高压、糖尿病、肥胖症、疼痛等。因此，本发明还公开了治疗或预防此类疾病和失调的方法，以及包含一种或多种吲唑化合物的药物组合物。本发明部分基于对一类新型 5-三唑取代的吲唑分子的发现，该类分子在调节蛋白激酶方面具有强效活性。因此，本发明包括口服活性分子和肠外活性分子，这些分子可以较低的剂量或血清浓度用于治疗与蛋白激酶信号转导有关的疾病或紊乱。
• Kolesnikow; Kabanowa, Izvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i Khimicheskaya Tekhnologiya, 1958, vol. 1, # 3, p. 66
  作者：Kolesnikow、Kabanowa

  DOI：——

  日期：——
• INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS
  申请人：Signal Pharmaceuticals LLC

  公开号：EP1692128A1

  公开（公告）日：2006-08-23